BARCELONA, Spain I March 13, 2025 I SpliceBio, a clinical-stage genetic medicines company pioneering Protein Splicing to address diseases caused by mutations ...
Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.
Researchers at Kumamoto University have successfully executed a practical trial of a new genome-editing technique that allows ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback